Morgan Stanley’s Odyssey Therapeutics ODTX Stock Holding History

Morgan Stanley’s Portfolio ODTX Stock Details ODTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.2K	Buy	+1,772	New	+$31.1K	﹤0.01%	6642

Other funds holding ODTX

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LMC

Lightspeed Management Company Menlo Park, California $2.4B AUM 7.07% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Morgan Stanley's ODTX Position: Q2 2026 in Review

Morgan Stanley opened a new position in Odyssey Therapeutics (ODTX) in Q2 2026: 1,772 shares worth $33.2K. The stake represents ﹤0.01% of the portfolio and ranks #6642 among its holdings.

50 funds tracked by Wall St. Rank hold ODTX as of Q2 2026.

Morgan Stanley held 1,772 shares of Odyssey Therapeutics worth $33.2K as of Q2 2026.
Odyssey Therapeutics was a new Morgan Stanley position in Q2 2026.
Odyssey Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6642 holding.
50 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.